Developing best-in-class allosteric inhibitors for RAS-driven cancers

Leading the Next Wave of Innovation in KRAS Therapy

KRAS mutations and amplifications are a driver in nearly one-quarter of all cancers. We are developing allosteric small molecules to target previously undruggable RAS mutations, such as KRASG12D and KRASG12V, in difficult to treat cancers, including pancreatic, colorectal, lung and endometrial cancer types. KRAS inhibitors have been developed to target the KRASG12C mutation, but these therapies are limited to only around ten percent of KRAS-driven cancers.

We are focused on modulation of RAS signaling at the cell membrane to broaden the scope of treatable RAS-driven cancers. We are applying deep biologic insight, unique protein conformation detection technology, sophisticated medicinal chemistry, and clinical development expertise to advance multiple, chemically distinct KRAS inhibitor programs with differentiated mechanisms of action. Our technology and capabilities are enabling the development of best-in-class, oral, small molecules with the potential to lead the next wave of innovation in KRAS therapy.

Our Leadership

OUR LEADERSHIP TEAM HAS AN UNWAVERING COMMITMENT TO HELPING PATIENTS WITH DIFFICULT-TO-TREAT CANCERS

We are an experienced team of RAS biology leaders, innovative medicinal chemists, and clinical development experts. The Quanta team brings together a scientific foundation based on discovery research from RAS signaling pioneers with extensive oncology-focused small molecule translational and clinical development experience. Collectively, our leadership team has contributed to the discovery, development, approval, and launch of multiple biopharmaceutical medicines.

Leadership Team

Perry Nisen, MD PhD
Chief Executive Officer

Cameron Pitt, PhD
Chief Operating Officer

Leonardo Faoro, MD, MBA
Chief Medical Officer

Hong Lin, PhD
SVP of Drug Discovery

Juan Luengo, PhD
SVP of Chemistry

Derek Metzger
SVP Corporate Strategy and Operations

Tina Woo
VP, Head of Development Operations

Mike Kramer
VP, Head of Scientific Operations

Elizabeth Donohue Vo, PhD
Sr Dir. of Biology

David H. Rominger
Sr. Dir. of Nonclinical Drug Development


Board of Directors

Samuel Saks, MD
Chairperson

Perry Nisen, MD PhD
CEO, Director

Cameron Pitt, PhD
COO, Director

Maha Katabi, PhD
Director

Arjun Goyal, MD
Director

Maria Fardis, PhD MBA
Director

Ying Huang, PhD
Director


Scientific Advisory Board

Frank McCormick, PhD FRS
UCSF

Andrej Sali, PhD
UCSF

Ben Cravatt, PhD
Scripps

Phil Baran, PhD
Scripps


Investors

sofinnova investments logo

vida ventures logo

avidity logo

surveyor logo

longitude capital logo

BVF partners logo

logos capital logo

abbvie logo

Our Pipeline

OUR PIPELINE AIMS TO ADDRESS A BROAD SPECTRUM OF RAS-DRIVEN CANCERS

Despite the approval of KRASG12C inhibitors, there remains a large patient population that may benefit from inhibition of other RAS mutations, particularly KRASG12D and KRASG12V, which are highly prevalent in cancers of the colon, pancreas and lung.

pipeline graphic

pipeline graphic

QUANTA’S ORALLY BIOAVAILABLE, CNS-PENETRANT KRAS INHIBITORS

Our pipeline includes multiple KRAS inhibitor programs from distinct chemical series, including our two lead assets, a G12D-preferring multi-KRAS candidate (QTX3034) and a G12D-selective candidate (QTX3046) currently being evaluated in Phase 1 clinical trials. We are also progressing QTX3544, a G12V-preferring multi-KRAS program, and plan to complete IND-enabling studies for this program in 2024. In preclinical studies, our candidates have demonstrated potent, selective, oral, CNS-penetrant properties. These data support the potential for our pipeline to significantly expand the scope of treatable KRAS-mutated cancers with direct, oral therapies.


Quanta’s novel RAS-Partner discovery program

Our unique conformation-sensitive Second Harmonic Generation (SHG) assays enable direct allosteric modulation of signaling complexes in the mitogen-activated protein kinase (MAPK) pathway to target a broad spectrum of RAS-driven tumors. These programs have potential as both monotherapies and synthetic lethal combination partners enhancing Quanta’s pipeline.

Our Platform

OUR PROPRIETARY PLATFORM ENABLES THE DISCOVERY OF ALLOSTERIC SMALL MOLECULES TO TARGET PREVIOUSLY UNDRUGGABLE KRAS MUTATIONS

laser icon

Our proprietary Second Harmonic Generation (SHG) platform is a high-throughput optical technology capable of measuring subtle changes in protein conformation for allosteric drug discovery. This enables the functional, structure-based discovery of small molecules that target previously “undruggable” signaling complexes.

 

drug icon

We then apply skilled medicinal chemistry approaches to novel, drug-like scaffolds to optimize lead compounds that demonstrate potent, selective inhibition of cancer cell signaling and attractive physicochemical properties.

 

Career Opportunities

We believe that everyone at Quanta plays a vital role in bringing best-in-class cancer medicines to patients in need

When we set out to make a superior class of medicines to address RAS-driven cancers, we intentionally created a work environment that was designed to foster that mission. A place where incredibly talented individuals are empowered to do their best work. As Quanta continues to grow, we will be guided by the principles that define us and we hope that they will serve each new employee who joins our team.

We are seeking highly motivated drug-hunters to join our passionate and experienced scientific team.

Please be alert to potential fraudulent recruiting efforts, such as when an individual not associated with Quanta Therapeutics pretends to be someone from Quanta. If you have been contacted about a role, please reach out to heather.meeks@quantatx.com to verify the authenticity of the position.


There are no positions available at this time.